Cargando…

A novel HER2 gene body enhancer contributes to HER2 expression

The transcriptional regulation of the human epidermal growth factor receptor-2 (HER2) contributes to an enhanced HER2 expression in HER2-positive breast cancers with HER2 gene amplification and HER2-low or HER2-negative breast cancers following radiotherapy or endocrine therapy, and this drives tumo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Q, Kulak, M V, Borcherding, N, Maina, P K, Zhang, W, Weigel, R J, Qi, H H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2018
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794618/ https://www.ncbi.nlm.nih.gov/pubmed/29035388 http://dx.doi.org/10.1038/onc.2017.382

Ejemplares similares

Contribution of synergism between PHF8 and HER2 signalling to breast cancer development and drug resistance
por: Liu, Qi, et al.
Publicado: (2020)

Methods for preparing tissue microarray slides using xenografts with different levels of HER2 expression to standardize HER2 detection
por: Yorozu, Keigo, et al.
Publicado: (2022)

Droplet digital PCR measurement of HER2 in patients with gastric cancer
por: Kinugasa, H, et al.
Publicado: (2015)

Frequency of HER2 expression of circulating tumour cells in patients with metastatic or recurrent gastrointestinal cancer
por: Iwatsuki, M, et al.
Publicado: (2013)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

Increased expression of EHF contributes to thyroid tumorigenesis through transcriptionally regulating HER2 and HER3
por: Lv, Yanyan, et al.
Publicado: (2016)

Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy
por: Arai, Roberto J., et al.
Publicado: (2018)

Cutaneous Adnexal Adenocarcinoma: Genomic Analysis and Successful HER2-targeted Therapy of Metastatic Disease
por: HIRANO-LOTMAN, Yui, et al.
Publicado: (2023)

Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas
por: Wang, Xin-Yu, et al.
Publicado: (2019)

Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer
por: Jacot, W, et al.
Publicado: (2004)

Enhertu (Fam-trastuzumab-deruxtecan-nxki) – Revolutionizing treatment paradigm for HER2-Low breast cancer
por: Siddiqui, Tasmiyah, et al.
Publicado: (2022)

Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis
por: Moss, Nelson S., et al.
Publicado: (2023)

A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells
por: Serwotka-Suszczak, Anna M., et al.
Publicado: (2017)

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
por: Cizkova, M, et al.
Publicado: (2013)

First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study
por: Aitelhaj, Meryem, et al.
Publicado: (2016)

CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer
por: Di Cosimo, Serena, et al.
Publicado: (2020)

HER-3 expression in HER-2-amplified breast carcinoma
por: Czopek, Jacek, et al.
Publicado: (2013)

DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study
por: Bon, Giulia, et al.
Publicado: (2023)

In situ quantification of HER2–protein tyrosine kinase 6 (PTK6) protein–protein complexes in paraffin sections from breast cancer tissues
por: Aubele, M, et al.
Publicado: (2010)

Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma
por: González-Alonso, Paula, et al.
Publicado: (2015)

HER-2 gene amplification in human breast cancer without concurrent HER-2 over-expression
por: Luoh, Shiuh-Wen, et al.
Publicado: (2013)

Targeting G(i/o) protein–coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy
por: Lyu, Cancan, et al.
Publicado: (2021)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

The ERα coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium
por: Rokicki, Jerzy, et al.
Publicado: (2010)

Functional analysis of a putative HER2-associated expressed enhancer, Her2-Enhancer1, in breast cancer cells
por: Rojhannezhad, Mahdieh, et al.
Publicado: (2023)

Novel agents that downregulate EGFR, HER2, and HER3 in parallel
por: Ferreira, Renan Barroso, et al.
Publicado: (2015)

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
por: Vicario, Rocio, et al.
Publicado: (2015)

Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells
por: Hosonaga, Mari, et al.
Publicado: (2014)

HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer
por: Chandran, Vineesh Indira, et al.
Publicado: (2015)

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
por: Shankaran, Harish, et al.
Publicado: (2013)

Monitoring serum HER2 levels in breast cancer patients
por: Tchou, Julia, et al.
Publicado: (2015)

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2006)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome()()
por: Siegfried, Jill M., et al.
Publicado: (2015)

Gene therapy using plasmid DNA-encoded anti-HER2 antibody for cancers that overexpress HER2
por: Kim, H, et al.
Publicado: (2016)

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
por: Atallah, N. M., et al.
Publicado: (2023)

Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells
por: Das, P M, et al.
Publicado: (2010)

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
por: Loibl, Sibylle, et al.
Publicado: (2022)

Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2
por: Kunisue, H, et al.
Publicado: (2000)

TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
por: Gu, Yayun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ki06rb8pkp2b19ss8g9dn7tqll